HighTower Advisors
KYNB

HighTower Advisors’s Kyntra Bio KYNB Stock Holding History

HighTower Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8
Closed -$2K – 2310
2019
Q4 		$2K Buy
+8
New +$8.17K ﹤0.01% 2247

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

HighTower Advisors's KYNB Position: Q1 2026 in Review

HighTower Advisors reduced its Kyntra Bio (KYNB) stake by 0.01% in Q1 2026, selling an estimated $16 and leaving 39,744 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #3258.

HighTower Advisors first reported a position in KYNB in Q4 2018 and has held it in 30 quarters since. The position peaked at $2.88M in Q3 2020. 32 funds tracked by Wall St. Rank hold KYNB as of Q1 2026.

  • HighTower Advisors held 39,744 shares of Kyntra Bio worth $269K as of Q1 2026.
  • HighTower Advisors sold 2 Kyntra Bio shares in Q1 2026, an estimated $16.
  • Kyntra Bio made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3258 holding.
  • HighTower Advisors first reported a position in Kyntra Bio in Q4 2018 and has held it in 30 quarters since.
  • HighTower Advisors's Kyntra Bio position peaked at $2.88M in Q3 2020.
  • 32 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.